Immuno-related cardio-vascular adverse events associated with immuno-oncological treatments: an under-estimated threat for cancer patients
Basic Research in Cardiology,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 3, 2024
Abstract
Immunotherapy
represents
an
emergent
and
heterogeneous
group
of
anticancer
treatments
harnessing
the
human
immune-surveillance
system,
including
immune-checkpoint
inhibitor
monoclonal
antibodies
(mAbs),
Chimeric
Antigen
Receptor
T
Cells
(CAR-T)
therapy,
cancer
vaccines
lymphocyte
activation
gene-3
(LAG-3)
therapy.
While
remarkably
effective
against
several
malignancies,
these
therapies,
often
in
combination
with
other
treatments,
have
showed
unforeseen
toxicity,
cardiovascular
complications.
The
occurrence
immuno-mediated
adverse
(irAEs)
events
has
been
progressively
reported
last
10
years.
These
irAEs
present
extended
range
severity,
from
self-limiting
to
life-threatening
conditions.
Although
recent
guidelines
CardioOncology
provided
important
evidence
managing
they
encompass
general
approaches.
However,
a
specific
focus
is
required
due
particular
etiology,
unique
risk
factors,
associated
side
effects
immunotherapy.
This
review
aims
deepen
understanding
prevalence
nature
issues
patients
undergoing
immunotherapy,
offering
insights
into
strategies
for
stratification
management.
Язык: Английский
Cardio-oncology: chances and challenges
Basic Research in Cardiology,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 30, 2024
Язык: Английский
Baicalin reduced vandetanib induced myocardial injury by regulating redox balance and NLRP3 inflammasome pathway
Tissue and Cell,
Год журнала:
2025,
Номер
94, С. 102795 - 102795
Опубликована: Фев. 16, 2025
Язык: Английский
Autoimmune-related adverse events induced by immune checkpoint inhibitors
Current Opinion in Immunology,
Год журнала:
2025,
Номер
94, С. 102556 - 102556
Опубликована: Апрель 11, 2025
Язык: Английский
The cardio-oncologic burden of breast cancer: molecular mechanisms and importance of preclinical models
Basic Research in Cardiology,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 2, 2024
Abstract
Breast
cancer,
the
most
prevalent
cancer
affecting
women
worldwide,
poses
a
significant
cardio-oncological
burden.
Despite
advancements
in
novel
therapeutic
strategies,
anthracyclines,
HER2
antagonists,
and
radiation
remain
cornerstones
of
oncological
treatment.
However,
each
carries
risk
cardiotoxicity,
though
molecular
mechanisms
underlying
these
adverse
effects
differ.
Common
include
DNA
damage
response,
increased
reactive
oxygen
species,
mitochondrial
dysfunction,
which
are
key
areas
ongoing
research
for
potential
cardioprotective
strategies.
Since
also
essential
effective
tumor
cytotoxicity,
we
explore
tumor-specific
effects,
particularly
hereditary
breast
linked
to
BRCA1
BRCA2
mutations.
These
genetic
variants
impair
repair
mechanisms,
increase
tumorigenesis
possibly
cardiotoxicity
from
treatments
such
as
anthracyclines
antagonists.
Novel
therapies,
including
immune
checkpoint
inhibitors,
used
clinic
triple-negative
improve
outcomes
patients.
This
review
discusses
BRCA
dysfunction
associated
pathological
pathways.
It
gives
an
overview
preclinical
models
genetically
engineered
mouse
models,
syngeneic
murine
humanized
various
vitro
ex
vivo
systems
study
cardiovascular
side
therapies.
Understanding
mechanism
developing
strategies
improving
treatment
reducing
long-term
risks
Язык: Английский